التفاصيل البيبلوغرافية
| العنوان: |
Post-authorization Safety Study (PASS) of Pediatric Patients Initiating Selumetinib Treatment for Symptomatic Inoperable Plexiform Neurofibromas (PNs) Associated with Neurofibromatosis Type 1 (NF1). |
| المؤلفون: |
Rosenbaum, T., Passos, J., Martin, L., Moiseenko, A., Obradovic, V., Amar, R., Dobrinsky, C., Brecht, I. |
| المصدر: |
Neuropediatrics; 2023 Supplement 1, Vol. 54, pS1-S32, 32p |
| مصطلحات موضوعية: |
CHILD patients, NEUROFIBROMATOSIS 1, BONE growth, PATIENT safety, SAFETY |
| مصطلحات جغرافية: |
UNITED Kingdom |
| الشركة/الكيان: |
EUROPEAN Union |
| مستخلص: |
This article discusses a post-authorization safety study (PASS) being conducted in the European Union and the United Kingdom to evaluate the safety profile of selumetinib, a MEK1/2 inhibitor, in pediatric patients with symptomatic inoperable plexiform neurofibromas (PNs) associated with neurofibromatosis type 1 (NF1). The study aims to characterize the long-term safety of selumetinib, including potential developmental effects, in children with NF1-associated PNs. The study will enroll a total of 125 patients and will collect data on safety outcomes such as cardiac function, bone development, muscle function, liver function, eye health, and pubertal development. The results of this study will provide valuable information on the safety of selumetinib in this patient population. [Extracted from the article] |
|
Copyright of Neuropediatrics is the property of Georg Thieme Verlag Stuttgart and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
